MiR-148a inhibits angiogenesis by targeting ERBB3

Area of Science:

• Oncology
• Molecular Biology
• Gene Regulation

Background:

• MicroRNAs (miRNAs) are critical regulators in carcinogenesis, with down-regulation observed in various solid tumors.
• The specific role and targets of microRNA-148a (miR-148a) in breast cancer remain largely unexplored.
• Previous studies indicate reduced miR-148a levels in certain cancer types.

Purpose of the Study:

• To investigate the biological function and molecular targets of miR-148a in human breast cancer.
• To elucidate the mechanism by which miR-148a influences breast cancer progression and angiogenesis.
• To identify potential therapeutic targets within the miR-148a signaling pathway.

Main Methods:

• Quantitative analysis of miR-148a levels in breast cancer cell lines (MCF7) compared to normal cells (MCF10A).
• Luciferase reporter assays to confirm direct binding of miR-148a to the 3'-UTR of V-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (ERBB3).
• In vitro and in vivo experiments assessing the effects of miR-148a overexpression on ERBB3 expression, downstream signaling pathways (AKT, ERK1/2, p70S6K1), HIF-1α levels, and tumor angiogenesis.

Main Results:

• miR-148a levels were significantly lower in MCF7 breast cancer cells compared to MCF10A cells.
• ERBB3 was identified as a direct target of miR-148a, with miR-148a binding to the ERBB3 3'-UTR.
• Overexpression of miR-148a in MCF7 cells led to decreased ERBB3 expression, inhibited AKT, ERK1/2, and p70S6K1 signaling, reduced HIF-1α expression, and attenuated tumor angiogenesis in vivo.

Conclusions:

• ERBB3 is a direct downstream target of miR-148a in human breast cancer cells.
• miR-148a suppresses breast cancer progression and tumor angiogenesis by inhibiting the ERBB3 signaling pathway.
• Targeting the miR-148a/ERBB3 axis presents a potential therapeutic strategy for breast cancer prevention and treatment.